{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:46:54Z","timestamp":1792025214752,"version":"4.4.0"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100012357","name":"LifeArc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012357","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"DOI":"10.1038\/s41416-026-03631-7","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:07:55Z","timestamp":1792022875000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Paediatric therapeutic development workshop on desmoplastic small round cell tumours"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2336-614X","authenticated-orcid":false,"given":"Joseph S.","family":"Baxter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.","family":"Molenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arushi","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Teresa","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikki","family":"Bowdidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Bowdidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2805-8079","authenticated-orcid":false,"given":"Bernadette","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"da Silva Moura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Daems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Danielson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solomon","family":"English","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Grohar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Halliwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3972-5087","authenticated-orcid":false,"given":"Paul","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2756-5813","authenticated-orcid":false,"given":"Pamela","family":"Kearns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Klebanoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Klaourakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ladanyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geffen","family":"Lass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Lawlor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne M.","family":"Linardic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6631-8554","authenticated-orcid":false,"given":"Joseph","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Metayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Torsten","family":"Meister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Minard-Colin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwan","family":"Oldham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2520-139X","authenticated-orcid":false,"given":"Daniel","family":"Orbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4815-6293","authenticated-orcid":false,"given":"Sandro","family":"Pasquali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reineke A.","family":"Schoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Sellar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6748-8678","authenticated-orcid":false,"given":"Janet","family":"Shipley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Sparber-Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Stacchiotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Tap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8659-5329","authenticated-orcid":false,"given":"Giovana Tardin","family":"Torrezan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3200-1297","authenticated-orcid":false,"given":"Danh D.","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"van de Wetering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madina","family":"Wane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3762-5050","authenticated-orcid":false,"given":"Joshua J.","family":"Waterfall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Vasquez-Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8738-5913","authenticated-orcid":false,"given":"Andrew DJ","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jenkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5562-1857","authenticated-orcid":false,"given":"Sophie","family":"Postel-Vinay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4463-5759","authenticated-orcid":false,"given":"Emily","family":"Slotkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of LifeArc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arushi","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solomon","family":"English","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Halliwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Klaourakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geffen","family":"Lass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Lawlor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwan","family":"Oldham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Innovative Therapies for Children with Cancer (ITCC)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Kearns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Cancer Research UK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Danielson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Cancer Grand Challenge Protect team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Daems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"key":"3631_CR1","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3390\/cancers13030498","volume":"13","author":"CA Mello","year":"2021","unstructured":"Mello CA, Campos FAB, Santos TG, Silva MLG, Torrezan GT, Costa FD, et al. Desmoplastic small round cell tumor: a review of main molecular abnormalities and emerging therapy. Cancers. 2021;13:498. https:\/\/doi.org\/10.3390\/cancers13030498.","journal-title":"Cancers"},{"key":"3631_CR2","unstructured":"WHO Blue Book. 2020 https:\/\/publications.iarc.who.int\/Book-And-Report-Series\/Who-Classification-Of-Tumours\/Soft-Tissue-And-Bone-Tumours-2020"},{"key":"3631_CR3","doi-asserted-by":"publisher","first-page":"6145","DOI":"10.4081\/rt.2016.6145","volume":"8","author":"MA Bent","year":"2016","unstructured":"Bent MA, Padilla BE, Goldsby RE, DuBois SG. Clinical characteristics and outcomes of pediatric patients with desmoplastic small round cell tumor. Rare Tumors. 2016;8:6145. https:\/\/doi.org\/10.4081\/rt.2016.6145.","journal-title":"Rare Tumors"},{"key":"3631_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s00383-025-05987-y","volume":"41","author":"D Wu","year":"2025","unstructured":"Wu D, Zhao L, Liao Z, Luo L, Yao X. Prognostic factors of desmoplastic small round cell tumor in children and adolescents: a population-based study. Pediatr Surg Int. 2025;41:84. https:\/\/doi.org\/10.1007\/s00383-025-05987-y.","journal-title":"Pediatr Surg Int"},{"key":"3631_CR5","doi-asserted-by":"publisher","first-page":"e0246958","DOI":"10.1371\/journal.pone.0246958","volume":"16","author":"G de Pinieux","year":"2021","unstructured":"de Pinieux G, Karanian M, Le Loarer F, Le Guellec S, Chabaud S, Terrier P, et al. NetSarc\/RePPS\/ResSos and French Sarcoma Group- Groupe d\u2019Etude des Tumeurs Osseuses (GSF-GETO) networks. Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network. PLoS One. 2021;16:e0246958. https:\/\/doi.org\/10.1371\/journal.pone.0246958.","journal-title":"PLoS One"},{"key":"3631_CR6","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1002\/cncr.33618","volume":"127","author":"S Stacchiotti","year":"2021","unstructured":"Stacchiotti S, Frezza AM, Blay JY, Baldini EH, Bonvalot S, Bov\u00e9e JVMG, et al. Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer. 2021;127:2934\u201342. https:\/\/doi.org\/10.1002\/cncr.33618.","journal-title":"Cancer"},{"key":"3631_CR7","doi-asserted-by":"publisher","DOI":"10.1177\/1179554920987107","volume":"15","author":"H Jeong","year":"2021","unstructured":"Jeong H, Hong YS, Kim YH, Kim CW, Song SY, Song JS, et al. The role and clinical effectiveness of multiline chemotherapy in advanced desmoplastic small round cell tumor. Clin Med Insights Oncol. 2021;15:1179554920987107. https:\/\/doi.org\/10.1177\/1179554920987107.","journal-title":"Clin Med Insights Oncol"},{"key":"3631_CR8","doi-asserted-by":"publisher","first-page":"4865","DOI":"10.1158\/1078-0432.CCR-18-0202","volume":"24","author":"V Subbiah","year":"2018","unstructured":"Subbiah V, Lamhamedi-Cherradi SE, Cuglievan B, Menegaz BA, Camacho P, Huh W, et al. Multimodality treatment of desmoplastic small round cell tumor: chemotherapy and complete cytoreductive surgery improve patient survival. Clin Cancer Res. 2018;24:4865\u201373. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0202.","journal-title":"Clin Cancer Res"},{"key":"3631_CR9","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/CCO.0b013e3283477aab","volume":"23","author":"A Hayes-Jordan","year":"2011","unstructured":"Hayes-Jordan A, Anderson PM. The diagnosis and management of desmoplastic small round cell tumor: a review. Curr Opin Oncol. 2011;23:385\u20139.","journal-title":"Curr Opin Oncol"},{"key":"3631_CR10","doi-asserted-by":"publisher","unstructured":"Bulbul A, Fahy BN, Xiu J, Rashad S, Mustafa A, Husain H et al. Desmoplastic small round blue cell tumor: a review of treatment and potential therapeutic genomic alterations. Sarcoma. 2017:1278268. https:\/\/doi.org\/10.1155\/2017\/1278268.","DOI":"10.1155\/2017\/1278268"},{"key":"3631_CR11","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/cam4.1940","volume":"8","author":"M Scheer","year":"2019","unstructured":"Scheer M, Vokuhl C, Blank B, Hallmen E, von Kalle T, M\u00fcnter M, et al. Desmoplastic small round cell tumors: multimodality treatment and new risk factors. Cancer Med. 2019;8:527\u201342.","journal-title":"Cancer Med"},{"key":"3631_CR12","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.2147\/CMAR.S368381","volume":"14","author":"A Ferrari","year":"2022","unstructured":"Ferrari A, Brennan B, Casanova M, Corradini N, Berlanga P, Schoot RA, et al. Pediatric non-rhabdomyosarcoma soft tissue sarcomas: standard of care and treatment recommendations from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancer Manag Res. 2022;14:2885\u2013902.","journal-title":"Cancer Manag Res"},{"key":"3631_CR13","doi-asserted-by":"publisher","unstructured":"Brahmi M, Romeo C, Meurgey A, Dupont M, Dufresne A. Desmoplastic small round cell tumor. Curr Opin Oncol. 2026. https:\/\/doi.org\/10.1097\/CCO.0000000000001239.","DOI":"10.1097\/CCO.0000000000001239"},{"key":"3631_CR14","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/00000478-199106000-00001","volume":"15","author":"WL Gerald","year":"1991","unstructured":"Gerald WL, Miller HK, Battifora H, Miettinen M, Silva EG, Rosai J. Intra-abdominal desmoplastic small round-cell tumor. Report of 19 cases of a distinctive type of high-grade polyphenotypic malignancy affecting young individuals. Am J Surg Pathol. 1991;15:499\u2013513.","journal-title":"Am J Surg Pathol"},{"key":"3631_CR15","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1097\/00000478-199811000-00001","volume":"22","author":"NG Ord\u00f3\u00f1ez","year":"1998","unstructured":"Ord\u00f3\u00f1ez NG. Desmoplastic small round cell tumor: I: a histopathologic study of 39 cases with emphasis on unusual histological patterns. Am J Surg Pathol. 1998;22:1303\u201313. https:\/\/doi.org\/10.1097\/00000478-199811000-00001.","journal-title":"Am J Surg Pathol"},{"key":"3631_CR16","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1097\/00000478-199811000-00002","volume":"22","author":"NG Ord\u00f3\u00f1ez","year":"1998","unstructured":"Ord\u00f3\u00f1ez NG. Desmoplastic small round cell tumor: II: an ultrastructural and immunohistochemical study with emphasis on new immunohistochemical markers. Am J Surg Pathol. 1998;22:1314\u201327. https:\/\/doi.org\/10.1097\/00000478-199811000-00002.","journal-title":"Am J Surg Pathol"},{"key":"3631_CR17","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.rmcr.2015.08.010","volume":"16","author":"MA Ariza-Prota","year":"2015","unstructured":"Ariza-Prota MA, Pando-Sandoval A, Fole-V\u00e1zquez D, Casan P. Desmoplastic small round cell tumor of the lung: a case report and literature review. Respir Med Case Rep. 2015;16:112\u20136. https:\/\/doi.org\/10.1016\/j.rmcr.2015.08.010.","journal-title":"Respir Med Case Rep"},{"key":"3631_CR18","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/01.pas.0000213432.14740.14","volume":"31","author":"LL Wang","year":"2007","unstructured":"Wang LL, Perlman EJ, Vujanic GM, Zuppan C, Brundler MA, Cheung CR, et al. Desmoplastic small round cell tumor of the kidney in childhood. Am J Surg Pathol. 2007;31:576\u201384. https:\/\/doi.org\/10.1097\/01.pas.0000213432.14740.14.","journal-title":"Am J Surg Pathol"},{"key":"3631_CR19","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/680126","volume":"2014","author":"CK Lettieri","year":"2014","unstructured":"Lettieri CK, Garcia-Filion P, Hingorani P. Incidence and outcomes of desmoplastic small round cell tumor: results from the surveillance, epidemiology, and end results database. J Cancer Epidemiol. 2014;2014:680126. https:\/\/doi.org\/10.1155\/2014\/680126.","journal-title":"J Cancer Epidemiol"},{"key":"3631_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30710-z","volume":"13","author":"SE Lamhamedi-Cherradi","year":"2022","unstructured":"Lamhamedi-Cherradi SE, Maitituoheti M, Menegaz BA, Krishnan S, Vetter AM, Camacho P, et al. The androgen receptor is a therapeutic target in desmoplastic small round cell sarcoma. Nat Commun. 2022;13:3057. https:\/\/doi.org\/10.1038\/s41467-022-30710-z.","journal-title":"Nat Commun"},{"key":"3631_CR21","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1245\/s10434-014-4289-y","volume":"22","author":"A Hayes-Jordan","year":"2015","unstructured":"Hayes-Jordan A, Green H, Lin H, Owusu-Agyemang P, Mejia R, et al. Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for children, adolescents, and young adults: the first 50 cases. Ann Surg Oncol. 2015;22:1726\u201332.","journal-title":"Ann Surg Oncol"},{"key":"3631_CR22","doi-asserted-by":"publisher","first-page":"e0171639","DOI":"10.1371\/journal.pone.0171639","volume":"12","author":"C Honore","year":"2017","unstructured":"Honore C, Atallah V, Mir O, Orbach D, Ferron G, LePe\u00b4choux C, et al. Abdominal desmoplastic small round cell tumor without extraperitoneal metastases: Is there a benefit for HIPEC after macroscopically complete cytoreductive surgery? PLoS ONE. 2017;12:e0171639.","journal-title":"PLoS ONE"},{"key":"3631_CR23","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.jpedsurg.2017.09.014","volume":"53","author":"O Zmora","year":"2018","unstructured":"Zmora O, Hayes-Jordan A, Nissan A, Kventsel I, Newmann Y, Itskovsky K, et al. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for disseminated intra-abdominal malignancies in children-a single-institution experience. J Pediatr Surg. 2018;53:1381\u20136.","journal-title":"J Pediatr Surg"},{"key":"3631_CR24","doi-asserted-by":"crossref","unstructured":"Issels RD, Lindner LH, Verweij J, Wessalowski R, Reichardt P, Wust P et al. Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients with Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial [published correction appears in JAMA Oncol. 2018 Apr 1; 4:590]. JAMA Oncol. 2018; 4:483-92.","DOI":"10.1001\/jamaoncol.2017.4996"},{"key":"3631_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27517","volume":"66","author":"J Gesche","year":"2019","unstructured":"Gesche J, Beckert S, Neunhoeffer F, Kachanov D, K\u00f6nigsrainer A, Seitz G, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A safe treatment option for intraperitoneal rhabdomyosarcoma in children below 5 years of age. Pediatr Blood Cancer. 2019;66:e27517.","journal-title":"Pediatr Blood Cancer"},{"key":"3631_CR26","doi-asserted-by":"publisher","first-page":"10694","DOI":"10.1002\/cam4.5829","volume":"12","author":"C Giani","year":"2023","unstructured":"Giani C, Radaelli S, Miceli R, Gandola L, Sangalli C, Frezza AM, et al. Long-term survivors with desmoplastic small round cell tumor (DSRCT): results from a retrospective single-institution case series analysis. Cancer Med. 2023;12:10694\u2013703. https:\/\/doi.org\/10.1002\/cam4.5829.","journal-title":"Cancer Med"},{"key":"3631_CR27","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1245\/s10434-019-07339-2","volume":"27","author":"ZE Stiles","year":"2020","unstructured":"Stiles ZE, Murphy AJ, Anghelescu DL, Brown CL, Davidoff AM, Dickson PV, et al. Desmoplastic small round cell tumor: long-term complications after cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2020;27:171\u20138. https:\/\/doi.org\/10.1245\/s10434-019-07339-2.","journal-title":"Ann Surg Oncol"},{"key":"3631_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101582","volume":"5","author":"C Henon","year":"2024","unstructured":"Henon C, Vibert J, Eychenne T, Gruel N, Colmet-Daage L, Ngo C, et al. Single-cell multiomics profiling reveals heterogeneous transcriptional programs and microenvironment in DSRCTs. Cell Rep Med. 2024;5:101582. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101582.","journal-title":"Cell Rep Med"},{"key":"3631_CR29","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1158\/1538-7445.AM2024-130","volume":"84","author":"D Truong","year":"2024","unstructured":"Truong D, Arslan E, Kochat V, Krishnan S, Agyemang C, Divenko M, et al. Abstract 130: Multi-omic analysis of desmoplastic small sound cell tumors reveal distinct epithelial and neuroendocrine lineages. Cancer Res. 2024;84:130.","journal-title":"Cancer Res"},{"key":"3631_CR30","doi-asserted-by":"publisher","first-page":"A070","DOI":"10.1158\/1538-7445.PEDIATRIC24-A070","volume":"84","author":"D Truong","year":"2024","unstructured":"Truong D, Arslan E, Kochat V, Krishnan S, Agyemang C, Divenko M, et al. Abstract A070: Identifying therapeutic vulnerabilities in desmoplastic small round cell tumor through multi-omics analyses. Cancer Res. 2024;84:A070\u2013A.","journal-title":"Cancer Res"},{"key":"3631_CR31","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1158\/1541-7786.MCR-20-0722","volume":"19","author":"EK Slotkin","year":"2021","unstructured":"Slotkin EK, Bowman AS, Levine MF, Dela Cruz F, Coutinho DF, Sanchez GI, et al. Comprehensive molecular profiling of desmoplastic small round cell tumor. Mol Cancer Res. 2021;19:1146\u201355. https:\/\/doi.org\/10.1158\/1541-7786.MCR-20-0722.","journal-title":"Mol Cancer Res"},{"key":"3631_CR32","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/00000478-199204000-00010","volume":"16","author":"JR Sawyer","year":"1992","unstructured":"Sawyer JR, Tryka AF, Lewis JM. A novel reciprocal chromosome translocation t(11;22)(p13;q12) in an intraabdominal desmoplastic small round-cell tumor. Am J Surg Pathol. 1992;16:411\u20136. https:\/\/doi.org\/10.1097\/00000478-199204000-00010.","journal-title":"Am J Surg Pathol"},{"key":"3631_CR33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/0165-4608(93)90105-u","volume":"69","author":"E Rodriguez","year":"1993","unstructured":"Rodriguez E, Sreekantaiah C, Gerald W, Reuter VE, Motzer RJ, Chaganti RS. A recurring translocation, t(11;22)(p13;q11.2), characterizes intra-abdominal desmoplastic small round-cell tumors. Cancer Genet Cytogenet. 1993;69:17\u201321. https:\/\/doi.org\/10.1016\/0165-4608(93)90105-u.","journal-title":"Cancer Genet Cytogenet"},{"key":"3631_CR34","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/gcc.2870070210","volume":"7","author":"JA Biegel","year":"1993","unstructured":"Biegel JA, Conard K, Brooks JJ. Translocation (11;22)(p13;q12): primary change in intra-abdominal desmoplastic small round cell tumor. Genes Chromosomes Cancer. 1993;7:119\u201321. https:\/\/doi.org\/10.1002\/gcc.2870070210.","journal-title":"Genes Chromosomes Cancer"},{"key":"3631_CR35","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1073\/pnas.92.4.1028","volume":"92","author":"WL Gerald","year":"1995","unstructured":"Gerald WL, Rosai J, Ladanyi M. Characterization of the genomic breakpoint and chimeric transcripts in the EWS-WT1 gene fusion of desmoplastic small round cell tumor. Proc Natl Acad Sci USA. 1995;92:1028\u201332. https:\/\/doi.org\/10.1073\/pnas.92.4.1028.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3631_CR36","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/ng1197-309","volume":"17","author":"SB Lee","year":"1997","unstructured":"Lee SB, Kolquist KA, Nichols K, Englert C, Maheswaran S, Ladanyi M, et al. The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumour. Nat Genet. 1997;17:309\u201313. https:\/\/doi.org\/10.1038\/ng1197-309. PMID: 9354795.","journal-title":"Nat Genet"},{"key":"3631_CR37","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1136\/jcp-2023-208867","volume":"77","author":"EA Towery","year":"2024","unstructured":"Towery EA, Papke DJ. EWSR1: the promiscuous king of mesenchymal neoplasia. J Clin Pathol. 2024;77:721\u20135.","journal-title":"J Clin Pathol"},{"key":"3631_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51851-3","volume":"15","author":"G Boulay","year":"2024","unstructured":"Boulay G, Broye LC, Dong R, Iyer S, Sanalkumar R, Xing YH, et al. EWS-WT1 fusion isoforms establish oncogenic programs and therapeutic vulnerabilities in desmoplastic small round cell tumors. Nat Commun. 2024;15:7460. https:\/\/doi.org\/10.1038\/s41467-024-51851-3.","journal-title":"Nat Commun"},{"key":"3631_CR39","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1158\/1078-0432.CCR-20-2585","volume":"27","author":"K Ogura","year":"2021","unstructured":"Ogura K, Somwar R, Hmeljak J, Magnan H, Benayed R, Momeni Boroujeni A, et al. Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor. Clin Cancer Res. 2021;27:1184\u201394.","journal-title":"Clin Cancer Res"},{"key":"3631_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104133","volume":"10","author":"M Brahmi","year":"2025","unstructured":"Brahmi M, Vanacker H, Dufresne A, Isnardi V, Dupont M, Meurgey A, et al. High expression level of ERBB2 and efficacy of trastuzumab deruxtecan in desmoplastic small round cell tumour: a monocentric case series report. ESMO Open. 2025;10:104133.","journal-title":"ESMO Open"},{"key":"3631_CR41","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1158\/1535-7163.MCT-25-0437","volume":"25","author":"CM Burke","year":"2026","unstructured":"Burke CM, Feinberg TY, Brosius S, Bhanot UK, Jain M, Linkov I, et al. Antitumor activity of trastuzumab deruxtecan in pediatric solid tumors with variable HER2 expression. Mol Cancer Ther. 2026;25:156\u201367.","journal-title":"Mol Cancer Ther"},{"key":"3631_CR42","doi-asserted-by":"publisher","DOI":"10.1200\/OA-25-00141","volume":"3","author":"EK Slotkin","year":"2026","unstructured":"Slotkin EK, Feinberg TY, Bhanot UK, Price A, Pandit-Taskar N, Domenico D, et al. Trastuzumab deruxtecan is active in desmoplastic small round cell tumor. JCO Oncol Adv. 2026;3:e2500141.","journal-title":"JCO Oncol Adv"},{"key":"3631_CR43","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3390\/cancers17060920","volume":"17","author":"L Seidmann","year":"2025","unstructured":"Seidmann L, Wingerter A, Oliver Metzig M, Bornas A, El Malki K, Ustjanzew A, et al. The chimeric antigen receptor T cell target claudin 6 is a marker for early organ-specific epithelial progenitors and is expressed in some pediatric solid tumor entities. Cancers (Basel). 2025;17:920. https:\/\/doi.org\/10.3390\/cancers17060920.","journal-title":"Cancers (Basel)"},{"key":"3631_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12881-020-01034-w","volume":"21","author":"WA Chow","year":"2020","unstructured":"Chow WA, Yee JK, Tsark W, Wu X, Qin H, Guan M, et al. Recurrent secondary genomic alterations in desmoplastic small round cell tumors. BMC Med Genet. 2020;21:101. https:\/\/doi.org\/10.1186\/s12881-020-01034-w.","journal-title":"BMC Med Genet"},{"key":"3631_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00257-9","volume":"6","author":"CC Wu","year":"2022","unstructured":"Wu CC, Beird HC, Lamhamedi-Cherradi SE, Soeung M, Ingram D, Truong DD, et al. Multi-site desmoplastic small round cell tumors are genetically related and immune-cold. NPJ Precis Oncol. 2022;6:21. https:\/\/doi.org\/10.1038\/s41698-022-00257-9.","journal-title":"NPJ Precis Oncol"},{"key":"3631_CR46","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00280-006-0280-z","volume":"59","author":"RL Fine","year":"2007","unstructured":"Fine RL, Shah SS, Moulton TA, Yu IR, Fogelman DR, Richardson M, et al. Androgen and c-Kit receptors in desmoplastic small round cell tumors resistant to chemotherapy: novel targets for therapy. Cancer Chemother Pharm. 2007;59:429\u201337. https:\/\/doi.org\/10.1007\/s00280-006-0280-z.","journal-title":"Cancer Chemother Pharm"},{"key":"3631_CR47","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s42003-024-06003-0","volume":"7","author":"JW Magrath","year":"2024","unstructured":"Magrath JW, Goldberg IN, Truong DD, Hartono AB, Sampath SS, Jackson CE, et al. Enzalutamide induces cytotoxicity in desmoplastic small round cell tumor independent of the androgen receptor. Commun Biol. 2024;7:411. https:\/\/doi.org\/10.1038\/s42003-024-06003-0.","journal-title":"Commun Biol"},{"key":"3631_CR48","doi-asserted-by":"publisher","unstructured":"Bulbul A, Shen JP, Xiu J, Tamayo P, Husain H. Genomic and proteomic alterations in desmoplastic small round blue-cell tumors. JCO Precis Oncol. 2018 1;2:PO.17.00170. https:\/\/doi.org\/10.1200\/PO.17.00170.","DOI":"10.1200\/PO.17.00170"},{"key":"3631_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-020-0224-1","volume":"9","author":"JM Gedminas","year":"2020","unstructured":"Gedminas JM, Chasse MH, McBrairty M, Beddows I, Kitchen-Goosen SM, Grohar PJ. Desmoplastic small round cell tumor is dependent on the EWS-WT1 transcription factor. Oncogenesis. 2020;9:41. https:\/\/doi.org\/10.1038\/s41389-020-0224-1. PMID: 32345977; PMCID: PMC7188842.","journal-title":"Oncogenesis"},{"key":"3631_CR50","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1158\/0008-5472.CAN-23-3334","volume":"84","author":"JW Magrath","year":"2024","unstructured":"Magrath JW, Sampath SS, Flinchum DA, Hartono AB, Goldberg IN, Boehling JR, et al. Comprehensive Transcriptomic Analysis of EWSR1::WT1 Targets Identifies CDK4\/6 Inhibitors as an Effective Therapy for Desmoplastic Small Round Cell Tumors. Cancer Res. 2024;84:1426\u201342. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-3334.","journal-title":"Cancer Res"},{"key":"3631_CR51","doi-asserted-by":"publisher","first-page":"4526","DOI":"10.1158\/0008-5472.CAN-13-3663","volume":"74","author":"HJ Kang","year":"2014","unstructured":"Kang HJ, Park JH, Chen W, Kang SI, Moroz K, Ladanyi M, et al. EWS-WT1 oncoprotein activates neuronal reprogramming factor ASCL1 and promotes neural differentiation. Cancer Res. 2014;74:4526\u201335. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-3663.","journal-title":"Cancer Res"},{"key":"3631_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3091-1","volume":"17","author":"S Uboldi","year":"2017","unstructured":"Uboldi S, Craparotta I, Colella G, Ronchetti E, Beltrame L, Vicario S, et al. Mechanism of action of trabectedin in desmoplastic small round cell tumor cells. BMC Cancer. 2017;17:107. https:\/\/doi.org\/10.1186\/s12885-017-3091-1.","journal-title":"BMC Cancer"},{"key":"3631_CR53","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.049649","volume":"16","author":"V Zuco","year":"2023","unstructured":"Zuco V, Pasquali S, Tortoreto M, Percio S, Doldi V, Barisella M, et al. Effectiveness of irinotecan plus trabectedin on a desmoplastic small round cell tumor patient-derived xenograft. Dis Model Mech. 2023;16:dmm049649. https:\/\/doi.org\/10.1242\/dmm.049649.","journal-title":"Dis Model Mech"},{"key":"3631_CR54","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1158\/1535-7163.MCT-21-1003","volume":"21","author":"JM Gedminas","year":"2022","unstructured":"Gedminas JM, Kaufman R, Boguslawski EA, Gross AC, Adams M, Beddows I, et al. Lurbinectedin inhibits the EWS-WT1 transcription factor in desmoplastic small round cell tumor. Mol Cancer Ther. 2022;21:1296\u2013305. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-1003.","journal-title":"Mol Cancer Ther"},{"key":"3631_CR55","doi-asserted-by":"publisher","unstructured":"Banks L, Arkin H, Chandran SS, Slotkin E, Shukla N, Morris L, et al. 343 Defining and therapeutically targeting a fusion-derived public neoantigen in desmoplastic small round cell tumor using T-cell receptor gene therapy. J Immunother Cancer. 2023;11. https:\/\/doi.org\/10.1136\/jitc-2023-SITC2023.0343","DOI":"10.1136\/jitc-2023-SITC2023.0343"},{"key":"3631_CR56","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1080\/14737140.2023.2200171","volume":"23","author":"S Hovsepyan","year":"2023","unstructured":"Hovsepyan S, Giani C, Pasquali S, Di Giannatale A, Chiaravalli S, Colombo C, et al. Desmoplastic small round cell tumor: from state of the art to future clinical prospects. Expert Rev anticancer Ther. 2023;23:471\u201384.","journal-title":"Expert Rev anticancer Ther"},{"key":"3631_CR57","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41586-023-06706-0","volume":"623","author":"M Yarmarkovich","year":"2023","unstructured":"Yarmarkovich M, Marshall QF, Warrington JM, Premaratne R, Farrel A, Groff D, et al. Targeting of intracellular oncoproteins with peptide-centric CARs. Nature. 2023;623:820\u20137. https:\/\/doi.org\/10.1038\/s41586-023-06706-0.","journal-title":"Nature"},{"key":"3631_CR58","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1038\/sj.leu.2404858","volume":"21","author":"JM Rojas","year":"2007","unstructured":"Rojas JM, Knight K, Wang L, Clark RE. Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia. 2007;21:2287\u201395.","journal-title":"Leukemia"},{"key":"3631_CR59","doi-asserted-by":"publisher","unstructured":"Powell A, Rabideau C, Monjure T, Subramaniam V, Sowers M, Hincapie N, et al. 1164 mRNA fusion-targeted vaccination elicits immune-mediated tumor killing. J Immunother Cancer. 2025;13. https:\/\/doi.org\/10.1136\/jitc-2025-SITC2025.1164","DOI":"10.1136\/jitc-2025-SITC2025.1164"},{"key":"3631_CR60","doi-asserted-by":"publisher","unstructured":"Thevasagayampillai S, Gunaratne PH, Kandasamy A, Adhikari D 939 Discovery of immunogenic neo-peptides from actionable RNA fusion FGFR3-TACC3 for developing cancer vaccines. J Immunother Cancer. 2025;13 https:\/\/doi.org\/10.1136\/jitc-2025-SITC2025.093.","DOI":"10.1136\/jitc-2025-SITC2025.093"},{"key":"3631_CR61","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1172\/JCI119152","volume":"99","author":"K Tanaka","year":"1997","unstructured":"Tanaka K, Iwakuma T, Harimaya K, Sato H, Iwamoto Y. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing\u2019s sarcoma and primitive neuroectodermal tumor cells. J Clin Investig. 1997;99:239\u20134.","journal-title":"J Clin Investig"},{"key":"3631_CR62","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1158\/1535-7163.MCT-06-0006","volume":"5","author":"V Rapozzi","year":"2006","unstructured":"Rapozzi V, Cogoi S, Xodo LE. Antisense locked nucleic acids efficiently suppress BCR\/ABL and induce cell growth decline and apoptosis in leukemic cells. Mol Cancer Ther. 2006;5:1683\u201392.","journal-title":"Mol Cancer Ther"},{"key":"3631_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18875-x","volume":"11","author":"M Martinez-Lage","year":"2020","unstructured":"Martinez-Lage M, Torres-Ruiz R, Puig-Serra P, Moreno-Gaona P, Martin MC, Moya FJ, et al. In vivo CRISPR\/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells. Nat Commun. 2020;11:5060.","journal-title":"Nat Commun"},{"key":"3631_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2025.201068","volume":"33","author":"MF Carle","year":"2025","unstructured":"Carle MF, Mohammadian Gol T, Antony JS, Roig-Merino A, Carter ME, Lauer UM, et al. Targeting oncogenic fusion-driven NUT carcinoma with CRISPR-Cas9 genome editing. Mol Ther Oncol. 2025;33:201068.","journal-title":"Mol Ther Oncol"},{"key":"3631_CR65","doi-asserted-by":"publisher","unstructured":"Yang H, Hulbatt RS, Kelleher A, Gratsch N, Wang, Palmbos PL et al. KLIPP - a precision CRISPR approach to target structural variant junctions in cancer. bioRxiv 2023.05.10.540176; https:\/\/doi.org\/10.1101\/2023.05.10.540176","DOI":"10.1101\/2023.05.10.540176"},{"key":"3631_CR66","doi-asserted-by":"publisher","unstructured":"Hu W, Chen H, Casan JML, Shembrey C, He S Brown LM et al. Systematic silencing of oncogenic fusion transcripts with ultra-precise CRISPR-Cas13b.bioRxiv 2025. 02. 10.637348; https:\/\/doi.org\/10.1101\/2025.02.10.637348","DOI":"10.1101\/2025.02.10.637348"},{"key":"3631_CR67","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1158\/0008-5472.CAN-18-0327","volume":"78","author":"JW Purcell","year":"2018","unstructured":"Purcell JW, Tanlimco SG, Hickson J, Fox M, Sho M, Durkin L, et al. LRRC15 is a novel mesenchymal protein and stromal target for antibody-drug conjugates. Cancer Res. 2018;78:4059\u201372. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-0327.","journal-title":"Cancer Res"},{"key":"3631_CR68","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1101\/gad.1110703","volume":"17","author":"PA Reynolds","year":"2003","unstructured":"Reynolds PA, Smolen GA, Palmer RE, Sgroi D, Yajnik V, Gerald WL, et al. Identification of a DNA-binding site and transcriptional target for the EWS-WT1(+KTS) oncoprotein. Genes Dev. 2003;17:2094\u2013107. https:\/\/doi.org\/10.1101\/gad.1110703.","journal-title":"Genes Dev"},{"key":"3631_CR69","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1210\/edrv-9-4-417","volume":"9","author":"SW Lamberts","year":"1988","unstructured":"Lamberts SW. The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endocr Rev. 1988;9:417\u201336. https:\/\/doi.org\/10.1210\/edrv-9-4-417.","journal-title":"Endocr Rev"},{"key":"3631_CR70","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/s1043-6618(05)80080-5","volume":"23","author":"G Schettini","year":"1991","unstructured":"Schettini G. Brain somatostatin: receptor-coupled transducing mechanisms and role in cognitive functions. Pharm Res. 1991;23:203\u201315. https:\/\/doi.org\/10.1016\/s1043-6618(05)80080-5.","journal-title":"Pharm Res"},{"key":"3631_CR71","doi-asserted-by":"publisher","first-page":"S1040","DOI":"10.1016\/j.annonc.2023.09.1165","volume":"34","author":"M Renner","year":"2023","unstructured":"Renner M, Ole\u015b M, Paramasivam N, Schneider A, Heilig CE, Modugno C, et al. 1936P Targeted therapy of desmoplastic small round cell tumor guided by multilayered molecular profiling. Ann Oncol. 2023;34:S1040.","journal-title":"Ann Oncol"},{"key":"3631_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-71636-0","volume":"17","author":"M Renner","year":"2026","unstructured":"Renner M, Ole\u015b M, Paramasivam N, Heilig CE, Schneider A, Modugno C, et al. Multi-layered molecular profiling informs the diagnosis and targeted therapy of desmoplastic small round cell tumor. Nat Commun. 2026;17:3397. https:\/\/doi.org\/10.1038\/s41467-026-71636-0.","journal-title":"Nat Commun"},{"key":"3631_CR73","doi-asserted-by":"publisher","first-page":"S1060","DOI":"10.1016\/j.annonc.2024.08.1875","volume":"35","author":"RF Schlenk","year":"2024","unstructured":"Schlenk RF, Heining C, Gnutzmann E, Roldan SSL, Heiligenthal L, Sparber Sauer M, et al. 1784TiP Pasireotide as maintenance treatment in SSTR2\/3\/5-expressing synovial sarcoma and desmoplastic small round cell tumor: The PAMSARC study. Ann Oncol. 2024;35:S1060.","journal-title":"Ann Oncol"},{"key":"3631_CR74","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.cell.2004.12.012","volume":"119","author":"Y Shi","year":"2004","unstructured":"Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004;119:941\u201353. https:\/\/doi.org\/10.1016\/j.cell.2004.12.012.","journal-title":"Cell"},{"key":"3631_CR75","doi-asserted-by":"publisher","first-page":"4851","DOI":"10.1128\/MCB.00521-10","volume":"30","author":"CT Foster","year":"2010","unstructured":"Foster CT, Dovey OM, Lezina L, Luo JL, Gant TW, Barlev N, et al. Lysine-specific demethylase 1 regulates the embryonic transcriptome and CoREST stability. Mol Cell Biol. 2010;30:4851\u201363. https:\/\/doi.org\/10.1128\/MCB.00521-10.","journal-title":"Mol Cell Biol"},{"key":"3631_CR76","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12929-021-00737-3","volume":"28","author":"D Kim","year":"2021","unstructured":"Kim D, Kim KI, Baek SH. Roles of lysine-specific demethylase 1 (LSD1) in homeostasis and diseases. J Biomed Sci. 2021;28:41. https:\/\/doi.org\/10.1186\/s12929-021-00737-3.","journal-title":"J Biomed Sci"},{"key":"3631_CR77","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1158\/0008-5472.CAN-08-1735","volume":"69","author":"JH Schulte","year":"2009","unstructured":"Schulte JH, Lim S, Schramm A, Friedrichs N, Koster J, Versteeg R, et al. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res. 2009;69:2065\u201371. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-1735.","journal-title":"Cancer Res"},{"key":"3631_CR78","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/ijc.25349","volume":"128","author":"S Hayami","year":"2011","unstructured":"Hayami S, Kelly JD, Cho HS, Yoshimatsu M, Unoki M, Tsunoda T, et al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer. 2011;128:574\u201386. https:\/\/doi.org\/10.1002\/ijc.25349.","journal-title":"Int J Cancer"},{"key":"3631_CR79","doi-asserted-by":"publisher","first-page":"e0118002","DOI":"10.1371\/journal.pone.0118002","volume":"10","author":"S Nagasawa","year":"2015","unstructured":"Nagasawa S, Sedukhina AS, Nakagawa Y, Maeda I, Kubota M, Ohnuma S, et al. LSD1 overexpression is associated with poor prognosis in basal-like breast cancer, and sensitivity to PARP inhibition. PLoS One. 2015;10:e0118002. https:\/\/doi.org\/10.1371\/journal.pone.0118002.","journal-title":"PLoS One"},{"key":"3631_CR80","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.3389\/fonc.2020.01234","volume":"10","author":"Q Xie","year":"2020","unstructured":"Xie Q, Tang T, Pang J, Xu J, Yang X, Wang L, et al. LSD1 promotes bladder cancer progression by upregulating LEF1 and enhancing EMT. Front Oncol. 2020;10:1234. https:\/\/doi.org\/10.3389\/fonc.2020.01234.","journal-title":"Front Oncol"},{"key":"3631_CR81","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/s41588-020-0681-7","volume":"52","author":"S Gao","year":"2020","unstructured":"Gao S, Chen S, Han D, Wang Z, Li M, Han W, et al. Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer. Nat Genet. 2020;52:1011\u20137. https:\/\/doi.org\/10.1038\/s41588-020-0681-7.","journal-title":"Nat Genet"},{"key":"3631_CR82","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/j.humpath.2010.12.025","volume":"42","author":"HU Schildhaus","year":"2011","unstructured":"Schildhaus HU, Riegel R, Hartmann W, Steiner S, Wardelmann E, Merkelbach-Bruse S, et al. Lysine-specific demethylase 1 is highly expressed in solitary fibrous tumors, synovial sarcomas, rhabdomyosarcomas, desmoplastic small round cell tumors, and malignant peripheral nerve sheath tumors. Hum Pathol. 2011;42:1667\u201375. https:\/\/doi.org\/10.1016\/j.humpath.2010.12.025.","journal-title":"Hum Pathol"},{"key":"3631_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1076581","volume":"12","author":"RD Dreher","year":"2023","unstructured":"Dreher RD, Theisen ER. Lysine specific demethylase 1 is a molecular driver and therapeutic target in sarcoma. Front Oncol. 2023;12:1076581. https:\/\/doi.org\/10.3389\/fonc.2022.1076581.","journal-title":"Front Oncol"},{"key":"3631_CR84","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27888","volume":"66","author":"A Romo-Morales","year":"2019","unstructured":"Romo-Morales A, Aladowicz E, Blagg J, Gatz SA, Shipley JM. Catalytic inhibition of KDM1A in Ewing sarcoma is insufficient as a therapeutic strategy. Pediatr Blood Cancer. 2019;66:e27888. https:\/\/doi.org\/10.1002\/pbc.27888.","journal-title":"Pediatr Blood Cancer"},{"key":"3631_CR85","doi-asserted-by":"publisher","unstructured":"Rask GC, Taslim C, Bayanjargal A, Cannon MV, Selich-Anderson J, Crow JC, et al. Seclidemstat blocks the transcriptional function of multiple FET-fusion oncoproteins. bioRxiv [Preprint]. 2024:2024.05.19.594897. https:\/\/doi.org\/10.1101\/2024.05.19.594897.","DOI":"10.1101\/2024.05.19.594897"},{"key":"3631_CR86","doi-asserted-by":"crossref","unstructured":"Reed DR, Chawla SP, Setty B, Mascarenhas L, Meyers PA, Metts J, et al. Phase expansion trial of the LSD1 inhibitor seclidemstat (SP-2577) with and without topotecan and cyclophosphamide (TC) in patients (pts) with relapsed or refractory Ewing sarcoma (ES) and select sarcomas. J Clin Oncol 39:TPS11577-TPS.","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS11577"},{"key":"3631_CR87","doi-asserted-by":"publisher","first-page":"21860","DOI":"10.1021\/acs.jmedchem.5c02246","volume":"68","author":"J Zhuo","year":"2025","unstructured":"Zhuo J, Zhai D, Liu L, Yin Y, Zhong C, Chen Q, et al. Discovery of LD-110 as an effective LSD1 PROTAC degrader for the treatment of esophagus squamous cancer. J Med Chem. 2025;68:21860\u201377.","journal-title":"J Med Chem"},{"key":"3631_CR88","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1158\/2767-9764.CRC-24-0296","volume":"5","author":"GC Rask","year":"2025","unstructured":"Rask GC, Taslim C, Bayanjargal A, Dreher RD, Cannon MV, Selich-Anderson J, et al. Seclidemstat (SP-2577) induces transcriptomic reprogramming and cytotoxicity in multiple fusion-positive sarcomas. Cancer Res Commun. 2025;5:1584\u201398.","journal-title":"Cancer Res Commun"},{"key":"3631_CR89","doi-asserted-by":"publisher","first-page":"43205","DOI":"10.1074\/jbc.M103810200","volume":"276","author":"N Reymond","year":"2001","unstructured":"Reymond N, Fabre S, Lecocq E, Adela\u00efde J, Dubreuil P, Lopez M. Nectin4\/PRR4, a new afadin-associated member of the nectin family that trans-interacts with nectin1\/PRR1 through V domain interaction. J Biol Chem. 2001;276:43205\u201315. https:\/\/doi.org\/10.1074\/jbc.M103810200.","journal-title":"J Biol Chem"},{"key":"3631_CR90","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","volume":"76","author":"PM Challita-Eid","year":"2016","unstructured":"Challita-Eid PM, Satpayev D, Yang P, An Z, Morrison K, Shostak Y, et al. Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res. 2016;76:3003\u201313. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1313.","journal-title":"Cancer Res"},{"key":"3631_CR91","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00432-025-06102-3","volume":"151","author":"JS Wang","year":"2025","unstructured":"Wang JS, Shapiro JC, Orlando S, Al-Marayaty R, Obeidin F, VanderWeele D, et al. Durable response to treatment of an atypical desmoplastic small round cell tumor with enfortumab-vedotin. J Cancer Res Clin Oncol. 2025;151:73. https:\/\/doi.org\/10.1007\/s00432-025-06102-3.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3631_CR92","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Dur\u00e1n I, Lee JL, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384:1125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2035807.","journal-title":"N Engl J Med"},{"key":"3631_CR93","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jamadermatol.2021.3450","volume":"157","author":"MN Nguyen","year":"2021","unstructured":"Nguyen MN, Reyes M, Jones SC. Postmarketing cases of enfortumab vedotin-associated skin reactions reported as stevens-johnson syndrome or toxic epidermal necrolysis. JAMA Dermatol. 2021;157:1237\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2021.3450.","journal-title":"JAMA Dermatol"},{"key":"3631_CR94","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s10555-025-10248-4","volume":"44","author":"P Ghosh","year":"2025","unstructured":"Ghosh P, Dey A, Nandi S, Majumder R, Das S, Mandal M. CTGF (CCN2): a multifaceted mediator in breast cancer progression and therapeutic targeting. Cancer Metastasis Rev. 2025;44:32. https:\/\/doi.org\/10.1007\/s10555-025-10248-4.","journal-title":"Cancer Metastasis Rev"},{"key":"3631_CR95","doi-asserted-by":"publisher","first-page":"12325","DOI":"10.1073\/pnas.1300415110","volume":"110","author":"A Neesse","year":"2013","unstructured":"Neesse A, Frese KK, Bapiro TE, Nakagawa T, Sternlicht MD, Seeley TW, et al. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proc Natl Acad Sci USA. 2013;110:12325\u201330. https:\/\/doi.org\/10.1073\/pnas.1300415110.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3631_CR96","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s11912-022-01211-5","volume":"24","author":"GM Ratnayake","year":"2022","unstructured":"Ratnayake GM, Laskaratos FM, Mandair D, Caplin ME, Rombouts K, Toumpanakis C. What causes desmoplastic reaction in small intestinal neuroendocrine neoplasms? Curr Oncol Rep. 2022;24:1281\u20136. https:\/\/doi.org\/10.1007\/s11912-022-01211-5.","journal-title":"Curr Oncol Rep"},{"key":"3631_CR97","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1136\/jcp.2003.012344","volume":"57","author":"AW Rachfal","year":"2004","unstructured":"Rachfal AW, Luquette MH, Brigstock DR. Expression of connective tissue growth factor (CCN2) in desmoplastic small round cell tumour. J Clin Pathol. 2004;57:422\u20135. https:\/\/doi.org\/10.1136\/jcp.2003.012344.","journal-title":"J Clin Pathol"},{"key":"3631_CR98","doi-asserted-by":"publisher","first-page":"38139","DOI":"10.1074\/jbc.M004901200","volume":"275","author":"P Stanhope-Baker","year":"2000","unstructured":"Stanhope-Baker P, Williams BR. Identification of connective tissue growth factor as a target of WT1 transcriptional regulation. J Biol Chem. 2000;275:38139\u201350. https:\/\/doi.org\/10.1074\/jbc.M004901200.","journal-title":"J Biol Chem"},{"key":"3631_CR99","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1158\/1535-7163.MCT-05-0516","volume":"5","author":"T Aikawa","year":"2006","unstructured":"Aikawa T, Gunn J, Spong SM, Klaus SJ, Korc M. Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer. Mol Cancer Ther. 2006;5:1108\u201316. https:\/\/doi.org\/10.1158\/1535-7163.MCT-05-0516.","journal-title":"Mol Cancer Ther"},{"key":"3631_CR100","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000668","volume":"5","author":"V Picozzi","year":"2020","unstructured":"Picozzi V, Alseidi A, Winter J, Pishvaian M, Mody K, Glaspy J, et al. Gemcitabine\/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer. ESMO Open. 2020;5:e000668. https:\/\/doi.org\/10.1136\/esmoopen-2019-000668.","journal-title":"ESMO Open"},{"key":"3631_CR101","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1104693","volume":"13","author":"M Espinosa-Cotton","year":"2023","unstructured":"Espinosa-Cotton M, Guo HF, Tickoo SK, Cheung NV. Identification of immunotherapy and radioimmunotherapy targets on desmoplastic small round cell tumors. Front Oncol. 2023;13:1104693. https:\/\/doi.org\/10.3389\/fonc.2023.1104693.","journal-title":"Front Oncol"},{"key":"3631_CR102","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1158\/1078-0432.CCR-24-1835","volume":"30","author":"T Zhang","year":"2024","unstructured":"Zhang T, Febres-Aldana CA, Liu Z, Dix JM, Cheng R, Dematteo RG. HER2 antibody-drug conjugates are active against desmoplastic small round cell tumor. Clin Cancer Res. 2024;30:4701\u201313. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1835.","journal-title":"Clin Cancer Res"},{"key":"3631_CR103","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.047621","volume":"15","author":"RS Smith","year":"2022","unstructured":"Smith RS, Odintsov I, Liu Z, Lui AJ, Hayashi T, Vojnic M, et al. Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signaling. Dis Model Mech. 2022;15:dmm047621. https:\/\/doi.org\/10.1242\/dmm.047621.","journal-title":"Dis Model Mech"},{"key":"3631_CR104","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.tips.2025.08.008","volume":"46","author":"DT Corrigan","year":"2025","unstructured":"Corrigan DT, Tanwar A, Du M, Martin AM, Zang X. The B7-H3 (CD276) pathway: emerging biology and clinical therapeutics. Trends Pharm Sci. 2025;46:975\u201388. https:\/\/doi.org\/10.1016\/j.tips.2025.08.008.","journal-title":"Trends Pharm Sci"},{"key":"3631_CR105","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.4049\/jimmunol.173.4.2500","volume":"173","author":"DV Prasad","year":"2004","unstructured":"Prasad DV, Nguyen T, Li Z, Yang Y, Duong J, Wang Y, et al. Murine B7-H3 is a negative regulator of T cells. J Immunol. 2004;173:2500\u20136. https:\/\/doi.org\/10.4049\/jimmunol.173.4.2500.","journal-title":"J Immunol"},{"key":"3631_CR106","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4135-x","volume":"18","author":"C Shi","year":"2018","unstructured":"Shi C, Feng Y, Zhang LC, Ding DY, Yan MY, Pan L. Effective treatment of apatinib in desmoplastic small round cell tumor: a case report and literature review. BMC Cancer. 2018;18:338. https:\/\/doi.org\/10.1186\/s12885-018-4135-x.","journal-title":"BMC Cancer"},{"key":"3631_CR107","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1200\/JCO.20.01974","volume":"38","author":"S Modak","year":"2020","unstructured":"Modak S, Zanzonico P, Grkovski M, Slotkin EK, Carrasquillo JA, Lyashchenko SK, et al. B7H3-directed intraperitoneal radioimmunotherapy with radioiodinated omburtamab for desmoplastic small round cell tumor and other peritoneal tumors: results of a phase I study. J Clin Oncol. 2020;38:4283\u201391. https:\/\/doi.org\/10.1200\/JCO.20.01974.","journal-title":"J Clin Oncol"},{"key":"3631_CR108","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1442488","volume":"12","author":"JW Magrath","year":"2024","unstructured":"Magrath JW, Espinosa-Cotton M, Flinchum DA, Sampath SS, Cheung NK, Lee SB. Desmoplastic small round cell tumor: from genomics to targets, potential paths to future therapeutics. Front Cell Dev Biol. 2024;12:1442488. https:\/\/doi.org\/10.3389\/fcell.2024.1442488.","journal-title":"Front Cell Dev Biol"},{"key":"3631_CR109","unstructured":"Food and Drug Administration. Pediatric Oncology: Promoting the development of safe and effective new drugs and biologics to treat cancer in children. 18 February 2026 [online] https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/pediatric-oncology (Accessed 6 June 2026)"},{"key":"3631_CR110","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/1878-0261.13577","volume":"18","author":"T Sugawara","year":"2024","unstructured":"Sugawara T, Nevedomskaya E, Heller S, B\u00f6hme A, Lesche R, von Ahsen O, et al. Dual targeting of the androgen receptor and PI3K\/AKT\/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis. Mol Oncol. 2024;18:726\u201342.","journal-title":"Mol Oncol"},{"key":"3631_CR111","doi-asserted-by":"crossref","unstructured":"Cardenas-Zuniga R, Ahmed AG, Cao KR, Raza A, Agyemang C, Truong D et al. Co-targeting AR, mTOR, and PI3K inhibitors in DSRCT as a novel therapeutic approach. Cancer Res 2025;85: Abstract nr 7036.","DOI":"10.1158\/1538-7445.AM2025-7036"},{"key":"3631_CR112","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1158\/0008-5472.CAN-23-3603","volume":"85","author":"A Kawai-Kawachi","year":"2025","unstructured":"Kawai-Kawachi A, Lenormand MM, Astier C, Herbel N, Cutrona MB, Ngo C, et al. Replication stress is an actionable genetic vulnerability in desmoplastic small round cell tumors. Cancer Res. 2025;85:154\u201370. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-3603.","journal-title":"Cancer Res"},{"key":"3631_CR113","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/nrm2852","volume":"11","author":"D Branzei","year":"2010","unstructured":"Branzei D, Foiani M. Maintaining genome stability at the replication fork. Nat Rev Mol Cell Biol. 2010;11:208\u201319. https:\/\/doi.org\/10.1038\/nrm2852.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3631_CR114","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.828684","volume":"12","author":"AB Bukhari","year":"2022","unstructured":"Bukhari AB, Chan GK, Gamper AM. Targeting the DNA damage response for cancer therapy by inhibiting the kinase Wee1. Front Oncol. 2022;12:828684. https:\/\/doi.org\/10.3389\/fonc.2022.828684.","journal-title":"Front Oncol"},{"key":"3631_CR115","doi-asserted-by":"publisher","DOI":"10.1200\/OA-24-00095","volume":"2","author":"EK Slotkin","year":"2025","unstructured":"Slotkin EK, Mauguen A, Dela Cruz FS, Ortiz MV, Avutu V, Meyers PA, et al. ACR-368, a CHK1\/2 kinase inhibitor, in patients with relapsed or refractory desmoplastic small round cell tumor: phase I\/II trial results. JCO Oncol Adv. 2025;2:e2400095.","journal-title":"JCO Oncol Adv"},{"key":"3631_CR116","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-69015-w","volume":"10","author":"P Hingorani","year":"2020","unstructured":"Hingorani P, Dinu V, Zhang X, Lei H, Shern JF, Park J, et al. Transcriptome analysis of desmoplastic small round cell tumors identifies actionable therapeutic targets: a report from the Children\u2019s Oncology Group. Sci Rep. 2020;10:12318. https:\/\/doi.org\/10.1038\/s41598-020-69015-w.","journal-title":"Sci Rep"},{"key":"3631_CR117","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107590","volume":"214","author":"KM Levine","year":"2020","unstructured":"Levine KM, Ding K, Chen L, Oesterreich S. FGFR4: A promising therapeutic target for breast cancer and other solid tumors. Pharm Ther. 2020;214:107590. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107590.","journal-title":"Pharm Ther"},{"key":"3631_CR118","doi-asserted-by":"publisher","first-page":"222","DOI":"10.2174\/1568009617666170427103732","volume":"18","author":"J Barroca-Ferreira","year":"2018","unstructured":"Barroca-Ferreira J, Pais JP, Santos MM, Goncalves AM, Gomes IM, Sousa I, et al. Targeting STEAP1 protein in human cancer: current trends and future challenges. Curr Cancer Drug Targets. 2018;18:222\u201330. https:\/\/doi.org\/10.2174\/1568009617666170427103732.","journal-title":"Curr Cancer Drug Targets"},{"key":"3631_CR119","unstructured":"Data for the Common Good [online] https:\/\/commons.cri.uchicago.edu (6 June 2026)."},{"key":"3631_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.103003","volume":"140","author":"S Stacchiotti","year":"2025","unstructured":"Stacchiotti S, Pantziarka P, Leonard H, Voltz C, Abatedaga L, Bouche G, et al. How to foster new treatment development in ultra-rare tumours? Joint EMA-EORTC multi-stakeholder workshops on ultra-rare sarcomas as a model for rare cancers. Cancer Treat Rev. 2025;140:103003.","journal-title":"Cancer Treat Rev"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03631-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03631-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03631-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:07:58Z","timestamp":1792022878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03631-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":120,"alternative-id":["3631"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03631-7","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"9 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JSB, AA, SE, EH, KK, GL, KL, SO, MW and DJ are employees of LifeArc. Andrew DJ Pearson is a consultant for LifeArc. CAK is a scientific co-founder and holds equity in Affini-T Therapeutics. CAK has previously consulted for, or is on the scientific and\/or clinical advisory boards of Achilles Therapeutics, Affini-T Therapeutics, Aleta BioTherapeutics, Bellicum Pharmaceuticals, BMS, Catamaran Bio, Cell Design Labs, Chronara Biosciences, Clasp Therapeutics, Decheng Capital, Genesis Therapeutics, G1 Therapeutics, Klus Pharma, Obsidian Therapeutics, PACT Pharma, Roche\/Genentech, Royalty Pharma, Stereo Biotherapeutics, and T-knife. All other authors have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}